These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 478303)
1. Drug combination may improve memory. Geriatrics; 1979 Oct; 34(10):15. PubMed ID: 478303 [No Abstract] [Full Text] [Related]
2. Oral physostigmine and lecithin improve memory in Alzheimer disease. Thal LJ; Fuld PA; Masur DM; Sharpless NS Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034 [TBL] [Abstract][Full Text] [Related]
3. Effects of physostigmine and lecithin on memory in Alzheimer disease. Peters BH; Levin HS Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419 [TBL] [Abstract][Full Text] [Related]
4. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Wettstein A Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183 [TBL] [Abstract][Full Text] [Related]
6. Memory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388 [No Abstract] [Full Text] [Related]
7. Neurochemical approaches to the treatment of senile dementia. Growdon JH; Corkin S Proc Annu Meet Am Psychopathol Assoc; 1980; 69():281-96. PubMed ID: 7413654 [No Abstract] [Full Text] [Related]
8. Physostigmine in the treatment of memory disorders: a case report. Denber HC Psychiatr J Univ Ott; 1982 Mar; 7(1):8-12. PubMed ID: 7051074 [No Abstract] [Full Text] [Related]
9. The effects of lecithin on memory in patients with senile dementia of the Alzheimer's type [proceedings]. Vroulis GA; Smith RC; Brinkman S; Schoolar J; Gordon J Psychopharmacol Bull; 1981 Jan; 17(1):127-8. PubMed ID: 7232644 [No Abstract] [Full Text] [Related]
10. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Thal LJ; Masur DM; Sharpless NS; Fuld PA; Davies P Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):627-36. PubMed ID: 3797688 [TBL] [Abstract][Full Text] [Related]
12. An update on the neurochemistry of Alzheimer disease. Davies P Adv Neurol; 1983; 38():75-86. PubMed ID: 6137134 [No Abstract] [Full Text] [Related]
13. [Psychopharmacologic treatment of cognitive function disorders in aging persons: current possibilities]. Jolles J; Verhoeven WM Tijdschr Gerontol Geriatr; 1984 Aug; 15(4):139-50. PubMed ID: 6091299 [TBL] [Abstract][Full Text] [Related]
14. Physostigmine and its effect on six patients with dementia. Ashford JW; Soldinger S; Schaeffer J; Cochran L; Jarvik LF Am J Psychiatry; 1981 Jun; 138(6):829-30. PubMed ID: 7246817 [No Abstract] [Full Text] [Related]
15. [Recent drug therapy of senile dementia]. Ohtomo E No To Shinkei; 1987 Jan; 39(1):49-58. PubMed ID: 3030382 [No Abstract] [Full Text] [Related]
16. Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease. N Engl J Med; 1983 Sep; 309(9):555-6. PubMed ID: 6877328 [No Abstract] [Full Text] [Related]
17. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Christie JE; Shering A; Ferguson J; Glen AI Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592 [TBL] [Abstract][Full Text] [Related]
18. A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease). Brinkman SD; Pomara N; Goodnick PJ; Barnett N; Domino EF J Clin Psychopharmacol; 1982 Aug; 2(4):281-5. PubMed ID: 7119136 [No Abstract] [Full Text] [Related]